Condition: Multiple Myeloma · Sponsor: GlaxoSmithKline
The study consists of three parts: Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different doses of unconjugated belantamab antibody in combination with a fixed dose of Belantamab mafodotin (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the unconjugated belantamab antibody in combination with the pomalidomide-dexamethasone (Pd) standard of care (SoC) backbone. The study will focus on participants with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Bullhead City, Arizona, United States | Recruiting |
| GSK Investigational Site | Pembroke Pines, Florida, United States | Recruiting |
| GSK Investigational Site | Grand Rapids, Michigan, United States | Recruiting |
| GSK Investigational Site | Chapel Hill, North Carolina, United States | Recruiting |
| GSK Investigational Site | Wilson, North Carolina, United States | Recruiting |
| GSK Investigational Site | Canton, Ohio, United States | Recruiting |
| GSK Investigational Site | Chattanooga, Tennessee, United States | Recruiting |
| GSK Investigational Site | Nashville, Tennessee, United States | Recruiting |
| GSK Investigational Site | Ciudadela, Argentina | Completed |
| GSK Investigational Site | Rosario, Argentina | Recruiting |
| GSK Investigational Site | San Juan Bautista, Argentina | Recruiting |
| GSK Investigational Site | Viedma, Argentina | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05714839